EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review

Lynn Malec, Davide Matino

Haemophilia · 2023-11 · 29 (6) · 1419-1429

DOI: 10.1111/hae.14866 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Haemophilia, online erschienen am 27.09.2023. Verfasst von Lynn Malec und 1 weiteren Autor:innen. Beteiligte Einrichtung: Versiti Blood Research Institute, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Hemophilia A. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical writing support was funded by Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The standard of care in severe haemophilia A is prophylaxis, which has historically aimed for a factor VIII (FVIII) trough level of ≥1%. However, despite prophylactic treatment, people with haemophilia remain at risk of bleeds that have physical and quality of life implications, and that impact everyday life.

Aim

The aim of this review was to evaluate evidence supporting the relationship between targeting higher FVIII activity levels with prophylaxis and improved outcomes in people with haemophilia A.

Methods

We conducted a narrative review that defined the unmet needs and treatment goals in people with haemophilia A, evaluated evidence to support targeting higher FVIII activity levels, and highlighted therapies that may support higher and sustained FVIII activity levels and improved outcomes for people with haemophilia A.

Results

Despite recent advances in treatment, unmet needs remain, and people with haemophilia continue to experience joint and functional impairment, acute and chronic pain, and poor mental health. All these negatively impact their health‐related quality of life. Evidence suggests that FVIII activity levels of up to 50% may be needed to achieve a near‐zero joint bleed rate. However, achieving high FVIII activity levels with current standard and extended half‐life (EHL) FVIII replacement therapies is associated with a high treatment burden. Innovative treatment options may provide high sustained FVIII activity levels and improved patient outcomes.

Conclusion

Evidence suggests that FVIII activity levels in people with haemophilia A should be sustained at higher levels to improve joint and patient outcomes and enable progression towards health equity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AHumansFactor VIIIQuality of LifeHemorrhageHemarthrosis

Stichwörter der Autor:innen

arthropathyfactor VIIIgene therapyhaemophilia Anon-factor replacement therapyprophylaxisquality of life

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.
  • Division of Hematology & Oncology, Departments of Medicine and Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Hematology & Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Förderung

  • Medical writing support was funded by Sanofi

Zitieren

APA

Malec, L., & Matino, D. (2023). Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia, 29(6), 1419-1429. https://doi.org/10.1111/hae.14866

Vancouver

Malec L, Matino D. Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review. Haemophilia. 2023;29(6):1419-1429. doi:10.1111/hae.14866

BibTeX
@article{Malec2023,
  author = {Malec, Lynn and Matino, Davide},
  title = {Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review},
  journal = {Haemophilia},
  year = {2023},
  volume = {29},
  number = {6},
  pages = {1419--1429},
  doi = {10.1111/hae.14866}
}
Kostenlos starten →